PartnershipJul 21, 2026, 04:12 PM
Jupiter Neurosciences Licenses ALA-002 from PharmAla
AI Summary
Jupiter Neurosciences, Inc. has entered into a definitive Strategic Asset License Agreement with PharmAla Biotech Holdings Inc. for the exclusive rights to develop, manufacture, and commercialize PharmAla’s ALA-002 program in the United States. The agreement includes an upfront payment of $3,333,333, consisting of cash and Jupiter common stock. Additionally, Jupiter will pay up to $23,333,333 in development milestones and up to $73,333,333 in commercialization milestones, along with a 3% royalty on net sales after certain thresholds are met.
Key Highlights
- Entered exclusive Strategic Asset License Agreement with PharmAla for ALA-002 in the US.
- Upfront payment of $3,333,333, comprising $1,500,000 cash and $1,833,333 in Jupiter common stock.
- Development milestone payments up to $23,333,333, including $3,333,333 for Phase 3 dosing and $20,000,000 for FDA approval.
- Commercialization milestone payments up to $73,333,333 based on net sales achievements.
- Royalty of 3% on net sales of Licensed Products in the Territory after the third commercialization milestone.
Price Impact
More from JUNS